SCHEMBL7540440

SCHEMBL7540440

COc1ccc(S(=O)(=O)c2c(F)c(F)c(NS(=O)(=O)c3ccccc3)c(F)c2F)cc1F

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CA12 O43570 1/20 0.50
CA9 Q16790 1/20 0.50
KMT2A Q03164 6/20 0.47
ALDH1A1 P00352 4/20 0.46
KDM4E B2RXH2 1/20 0.46
MEP1B Q16820 1/20 0.46
HPGD P15428 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.46
HTR6 P50406 1/20 0.46
LMNA P02545 4/20 0.45
MAPT P10636 2/20 0.45
KEAP1 Q14145 1/20 0.45
NFE2L2 Q16236 1/20 0.45
MEN1 O00255 5/20 0.45
SMN1; SMN2 Q16637 1/20 0.44
SLC40A1 Q9NP59 1/20 0.44
THRB P10828 1/20 0.44
HTT P42858 1/20 0.44
PKM P14618 1/20 0.44
TSHR P16473 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7536278 0.88 MEN1 (0.51) CA12CA9KMT2AALDH1A1KDM4E
SCHEMBL7536395 0.86 KMT2A (0.47) KMT2AALDH1A1MEP1BLMNAMAPT
SCHEMBL7534183 0.84 HTR6 (0.56) CA12CA9KMT2AALDH1A1HTR6
SCHEMBL7537217 0.83 KMT2A (0.44) KMT2AALDH1A1MEP1BLMNAMAPT
SCHEMBL7535778 0.83 MAPK1 (0.53) KMT2AMEP1BLMNAHTTTSHR
SCHEMBL7536275 0.82 KMT2A (0.60) KMT2AALDH1A1MAPTKEAP1NFE2L2
SCHEMBL22095988 0.80 CA12 (0.76) CA12CA9KMT2AALDH1A1LMNA
SCHEMBL8661766 0.78 PTGS2 (0.48) CA12CA9KMT2AALDH1A1KDM4E
SCHEMBL7533758 0.78 MEP1B (0.50) KMT2AMEP1BLMNAHTTTSHR
SCHEMBL3409664 0.78 HTR6 (0.66) CA12CA9KMT2AALDH1A1HTR6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents AMGEN INC. 2002-01-31 US claimed
EP-1005453-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK, INC. (US) 2000-06-07 EP claimed
WO-1999010320-A1 SUBSTITUTED BENZENE COMPOUNDS AS ANTIPROLIFERATIVE AND CHOLESTEROL LOWERING AGENTS TULARIK INC. (US) 1999-03-04 WO claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020013496-A1 Benzene compounds as antiproliferative and cholesterol lowering agents CYP46A1, TGFB1, NR1H2 CA12 4726/4885CA9 3379/4885KMT2A 3154/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.